Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 305-313

  Ogle, Laura F ^a   Orr, James G ^b   Willoughby, Catherine E ^a   Hutton, Claire ^a   McPherson, Stuart ^b   Plummer, Ruth ^a,b   Boddy, Alan V ^a   Curtin, Nicola J ^a   Jamieson, David ^a   Reeves, Helen L ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Circulating tumour cells; Hepatocellular cancer; ImageStream; Liquid biopsy

Indexed keywords

ALPHA FETOPROTEIN; CYTOKERATIN; DNA DEPENDENT KINASE; EPITHELIAL CELL ADHESION MOLECULE; GLYPICAN 3; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; TUMOR MARKER;

AGED; ARTICLE; BIOPSY; BLOOD ANALYSIS; BRAIN DISEASE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CELL SIZE; CELL STRUCTURE; CHEMOEMBOLIZATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA CONTENT; FEMALE; FLOW CYTOMETER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LEUKOCYTE; LIQUID BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MOLECULAR IMAGING; NEUTROPHIL; NONHUMAN; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; LIVER TUMOR; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; HUMANS; LIQUID BIOPSY; LIVER NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84973621072     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.014     Document Type: Article

References (25)

1. [1] International agency for research on cancer. 2014, World Cancer Report: World Health Organisation.
2. [2] J. Dyson, B. Jaques, Chattopadyhay, D., Lochan, R., Graham, J., Das, D., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
3. [3] EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
4. [4] Ashworth, T.R., A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 14 (1869), 146–147.
5. [5] Hayes, D.F., Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Miller, M.C., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12 (2006), 4218–4224.
6. [6] de Bono, J.S., Scher, H.I., Montgomery, R.B., Parker, C., Miller, M.C., Tissing, H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14 (2008), 6302–6309.
7. [7] Cohen, S.J., Punt, C.J.A., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 3213–3221.
8. [8] Zee, B.C., Wong, C., Kuhn, T., Howard, R., Yeo, W., Koh, J., et al. Detection of circulating tumor cells (CTCs) in patients with hepatocellular carcinoma (HCC). J Clin Oncol, 25, 2007, 15037.
9. [9] Morris, K.L., Tugwood, J.D., Khoja, L., Lancashire, M., Sloane, R., Burt, D., et al. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol 74 (2014), 323–332.
10. [10] Schulze, K., Gasch, C., Staufer, K., Nashan, B., Lohse, A.W., Pantel, K., et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133 (2013), 2165–2171.
11. [11] Vona, G., Sabile, A., Louha, M., Sitruk, V., Romana, S., Schutze, K., et al. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 156 (2000), 57–63.
12. [12] J. Li, L. Chen, X. Zhang, Zhang, Y., Liu, H., Sun, B., et al. Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. PLoS One, 9, 2014, e96185.
13. [13] Xu, W., Cao, L., Chen, L., Li, J., Zhang, X.F., Qian, H.H., et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res 17 (2011), 3783–3793.
14. [14] Dent, B.M., Ogle, L.F., O'Donnell, R.L., Hayes, N., Malik, U., Curtin, N.J., et al. High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Int J Cancer 138 (2016), 206–216.
15. [15] Cornell, L., Munck, J.M., Alsinet, C., Villanueva, A., Ogle, L., Willoughby, C.E., et al. DNA-PK-A Candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. Clin Cancer Res 21 (2015), 925–933.
16. [16] Byun, S., Son, S., Amodei, D., Cermak, N., Shaw, J., Kang, J.H., et al. Characterizing deformability and surface friction of cancer cells. Proc Natl Acad Sci U S A 110 (2013), 7580–7585.
17. [17] Alix-Panabieres, C., Pantel, K., Challenges in circulating tumour cell research. Nat Rev Cancer 14 (2014), 623–631.
18. [18] Nel, I., Baba, H.A., Ertle, J., Weber, F., Sitek, B., Eisenacher, M., et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 6 (2013), 420–428.
19. [19] Circulating tumor cells present EMT marks in human cancers. Cancer Discovery, 1, 2011, 192.
20. [20] Janssen Diagnostics. How does the CELLSEARCH® System work? 2015.
21. [21] El-Sayed, S.S., El-Sadany, M., Tabll, A.A., Soltan, A., El-Dosoky, I., Attallah, A.M., DNA ploidy and liver cell dysplasia in liver biopsies from patients with liver cirrhosis. Can J Gastroenterol 18 (2004), 87–91.
22. [22] Zhou, S.L., Dai, Z., Zhou, Z.J., Wang, X.Y., Yang, G.H., Wang, Z., et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 56 (2012), 2242–2254.
23. [23] S.L. Zhou, Z.J. Zhou, Z.Q. Hu, X. Li, Huang, X.W., Wang, Z., et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling. Cancer Lett 358 (2015), 124–135.
24. [24] Y.M. Li, S.C. Xu, Li, J., Han, K.Q., Pi, H.F., Zheng, L., et al. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease. Cell Death Dis, 4, 2013, e831.
25. [25] Klein, C.A., Parallel progression of primary tumours and metastases. Nat Rev Cancer 9 (2009), 302–312.